These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24779772)

  • 21. Studies of cannabinoid-1 receptor antagonists for the treatment of obesity: hologram QSAR model for biarylpyrazolyl oxadiazole ligands.
    Ye M; Dawson MI
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3310-5. PubMed ID: 19427207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural insight on the activity of type 1 angiotensin II peptide antagonists using MD simulations.
    Preto MA; Melo A; Rodrigues LM; Maia HL; Ramos MJ
    J Phys Chem B; 2008 Oct; 112(43):13620-8. PubMed ID: 18834172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
    Patny A; Desai PV; Avery MA
    Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
    Zhang J; Wang JL; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Bioorg Med Chem; 2012 Jul; 20(14):4208-16. PubMed ID: 22727371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
    Salum Lde B; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An ab initio study of AT2 antagonists.
    Jain S; Yadav A
    Chem Biol Drug Des; 2008 Mar; 71(3):271-7. PubMed ID: 18248348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
    Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
    Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.
    Ohno K; Amano Y; Kakuta H; Niimi T; Takakura S; Orita M; Miyata K; Sakashita H; Takeuchi M; Komuro I; Higaki J; Horiuchi M; Kim-Mitsuyama S; Mori Y; Morishita R; Yamagishi S
    Biochem Biophys Res Commun; 2011 Jan; 404(1):434-7. PubMed ID: 21130741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.
    Łukawski K; Janowska A; Jakubus T; Tochman-Gawda A; Czuczwar SJ
    Eur J Pharmacol; 2010 Aug; 640(1-3):172-7. PubMed ID: 20465998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanisms underlying angiotensin II-independent activation of angiotensin II type 1 receptor].
    Akazawa H; Komuro I
    Nihon Rinsho; 2012 Sep; 70(9):1492-8. PubMed ID: 23012793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor.
    Kellici TF; Ntountaniotis D; Kritsi E; Zervou M; Zoumpoulakis P; Potamitis C; Durdagi S; Salmas RE; Ergun G; Gokdemir E; Halabalaki M; Gerothanassis IP; Liapakis G; Tzakos A; Mavromoustakos T
    Curr Med Chem; 2016; 23(1):36-59. PubMed ID: 26572611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors.
    Kellici TF; Tzakos AG; Mavromoustakos T
    Molecules; 2015 Mar; 20(3):3868-97. PubMed ID: 25738535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis.
    Tuccinardi T; Calderone V; Rapposelli S; Martinelli A
    J Med Chem; 2006 Jul; 49(14):4305-16. PubMed ID: 16821790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-activity relationship study of some triazolinone based compounds with antagonistic balanced activity on angiotensin II receptor subtypes AT1 and AT2. A three-dimensional quantitative structure-activity relationship investigation.
    Pandya T; Chaturvedi SC
    Arzneimittelforschung; 2005; 55(5):265-70. PubMed ID: 15960425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facile and efficient syntheses of a series of N-benzyl and N-biphenylmethyl substituted imidazole derivatives based on (E)-urocanic acid, as angiotensin II AT1 receptor blockers.
    Agelis G; Kelaidonis K; Resvani A; Kalavrizioti D; Androutsou ME; Plotas P; Vlahakos D; Koukoulitsa C; Tselios T; Mavromoustakos T; Matsoukas J
    Molecules; 2013 Jun; 18(7):7510-32. PubMed ID: 23807577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking.
    Sokkar P; Mohandass S; Ramachandran M
    J Mol Model; 2011 Jul; 17(7):1565-77. PubMed ID: 20924625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.
    Zhang H; Unal H; Gati C; Han GW; Liu W; Zatsepin NA; James D; Wang D; Nelson G; Weierstall U; Sawaya MR; Xu Q; Messerschmidt M; Williams GJ; Boutet S; Yefanov OM; White TA; Wang C; Ishchenko A; Tirupula KC; Desnoyer R; Coe J; Conrad CE; Fromme P; Stevens RC; Katritch V; Karnik SS; Cherezov V
    Cell; 2015 May; 161(4):833-44. PubMed ID: 25913193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological significance of the interplay between angiotensin receptors: MAS receptors as putative final mediators of the effects elicited by angiotensin AT1 receptors antagonists.
    Pernomian L; Pernomian L; Gomes MS; da Silva CH
    Eur J Pharmacol; 2015 Dec; 769():143-6. PubMed ID: 26548625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers.
    Prusty SK; Sahu PK; Subudhi BB
    Mini Rev Med Chem; 2017; 17(6):518-528. PubMed ID: 27781960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.